Galectin Therapeutics, Inc. (GALT)
3.90
+0.14
(+3.72%)
USD |
NASDAQ |
Oct 02, 16:00
3.85
-0.05
(-1.28%)
After-Hours: 20:00
Galectin Therapeutics Max Drawdown (5Y) : 88.76% for Sept. 30, 2026
Max Drawdown (5Y) Chart
Historical Max Drawdown (5Y) Data
| Date | Value |
|---|---|
| September 30, 2026 | 88.76% |
| August 31, 2026 | 88.76% |
| July 31, 2026 | 88.76% |
| June 30, 2026 | 88.76% |
| May 31, 2026 | 88.76% |
| April 30, 2026 | 88.76% |
| March 31, 2026 | 88.76% |
| February 28, 2026 | 88.76% |
| January 31, 2026 | 88.76% |
| December 31, 2025 | 88.76% |
| November 30, 2025 | 88.76% |
| October 31, 2025 | 88.76% |
| September 30, 2025 | 88.76% |
| August 31, 2025 | 88.76% |
| July 31, 2025 | 88.76% |
| June 30, 2025 | 88.76% |
| May 31, 2025 | 88.76% |
| April 30, 2025 | 88.76% |
| March 31, 2025 | 88.76% |
| February 28, 2025 | 88.76% |
| January 31, 2025 | 88.76% |
| December 31, 2024 | 88.76% |
| November 30, 2024 | 88.76% |
| October 31, 2024 | 88.76% |
| September 30, 2024 | 88.76% |
| Date | Value |
|---|---|
| August 31, 2024 | 88.76% |
| July 31, 2024 | 88.76% |
| June 30, 2024 | 88.76% |
| May 31, 2024 | 88.76% |
| April 30, 2024 | 88.76% |
| March 31, 2024 | 88.76% |
| February 29, 2024 | 88.76% |
| January 31, 2024 | 88.76% |
| December 31, 2023 | 88.76% |
| November 30, 2023 | 88.76% |
| October 31, 2023 | 88.76% |
| September 30, 2023 | 88.76% |
| August 31, 2023 | 88.76% |
| July 31, 2023 | 88.76% |
| June 30, 2023 | 88.76% |
| May 31, 2023 | 88.76% |
| April 30, 2023 | 88.76% |
| March 31, 2023 | 88.76% |
| February 28, 2023 | 88.76% |
| January 31, 2023 | 88.76% |
| December 31, 2022 | 88.76% |
| November 30, 2022 | 91.58% |
| October 31, 2022 | 91.58% |
| September 30, 2022 | 91.58% |
| August 31, 2022 | 91.58% |
Max Drawdown Definition
Max drawdown is an indicator of the risk of a portfolio chosen based on a certain strategy. It measures the largest single drop from peak to bottom in the value of a portfolio before a new peak is achieved.
Max Drawdown (5Y) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Max Drawdown (5Y) Benchmarks
| Mirum Pharmaceuticals, Inc. | 50.92% |
| ACADIA Pharmaceuticals, Inc. | 77.18% |
| Alnylam Pharmaceuticals, Inc. | 58.17% |
| Savara, Inc. | 93.79% |
| Vericel Corp. | 73.97% |
Max Drawdown (5Y) Related Metrics
| Alpha (5Y) | -7.565 |
| Beta (5Y) | 0.3777 |
| Annualized Standard Deviation of Monthly Returns (5Y Lookback) | 92.46% |
| Historical Sharpe Ratio (5Y) | -0.0409 |
| Historical Sortino (5Y) | -0.0991 |
| Monthly Value at Risk (VaR) 5% (5Y Lookback) | 27.86% |